Donald Rumsfeld Is The Chairman Of Gilead
"Gilead Sciences" began in 1988, and Donald Rumsfeld was one of the
founding players. In 1992, Dr. John Martin entered into the field of
genetics in cooperation with two Israeli-connected companies. In 1990,
Gilead entered into a collaborative research agreement with Glaxo for
the research and development of genetic-code blockers, also known as
Anti-Sense. In June 1996, Gilead launched its first commercial
product, Vistide, for the treatment of patients with AIDS. And in
1999, Gilead's Tamiflu gained government approval for the treatment of
flu influenza.
Vistide achieved first approval in 2001 for the treatment of HIV.
In January of 1997, Donald Rumsfeld, a Gilead Board member since 1988,
was appointed Chairman of the company.
